This is the first study known to the authors to analyze the effect of medicine/device patent synergies in several therapeutic areas where they prevail: inhaled medicines for treating asthma and COPD, auto-injectors for treating anaphylaxis, and insulin pens for the treatment of type 1 (insulin dependent) diabetes. This evidence concerns the gene INS and asthma.